Oh Jiwon, O'Connor Paul W
Department of Neurology (JO), Johns Hopkins University, Baltimore, MD; and Division of Neurology, Department of Medicine (JO, PWO), St. Michael's Hospital, University of Toronto, Toronto, Canada.
Neurol Clin Pract. 2013 Jun;3(3):254-260. doi: 10.1212/CPJ.0b013e318296f299.
Teriflunomide is a novel disease-modifying agent that was recently approved for use in the treatment of multiple sclerosis (MS). Teriflunomide has demonstrated clinical efficacy and safety in a number of large, multicenter, phase III clinical trials and is an attractive agent to add to the growing repertoire of available treatments for MS, as it has the benefit of oral administration. Furthermore, existing clinical experience with its parent drug, leflunomide, provides indirect long-term safety data. This review summarizes teriflunomide's pharmacologic properties, pivotal clinical trials, and safety profile, and ends with a discussion of the role of teriflunomide in the context of current and emerging MS treatment options.
特立氟胺是一种新型疾病修正药物，最近被批准用于治疗多发性硬化症（MS）。特立氟胺在多项大型多中心III期临床试验中已证明其临床疗效和安全性，并且由于其具有口服给药的优势，是可添加到不断增加的MS可用治疗药物中的一种有吸引力的药物。此外，其母体药物来氟米特的现有临床经验提供了间接的长期安全性数据。本综述总结了特立氟胺的药理特性、关键临床试验和安全性概况，并最后讨论了特立氟胺在当前和新兴的MS治疗选择背景下的作用。
